Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMayo Hospital Lahore
About this trial
The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin.
The main questions it aims to answer are:
Does rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin?
What medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin?
Researchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery.
Participants will:
Take rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery
Undergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery
Be monitored for bleeding, complications, and other side effects
Eligibility criteria
Qualifiers
Both male or female patients
Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic
Patients with expected immobility for more than 24 hours
Disqualifiers
Patients with diagnosed pre-operative DVT
BMI more than 40
Patient who are on mechanical ventilation post operatively
Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident
Trial design
Treatments tested in this trial
- rivaroxaban (10mg)
- Enoxaparin 40 mg SC
Treatment groups
212 Participants
are divided into 2 treatment groupsSponsors and collaborators
Mayo Hospital Lahore
Lead sponsor
King Edward Medical University
Collaborator
Source ClinicalTrials.gov